Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT)
LABT Stock Price Chart
Explore Lakewood-Amedex Biotherapeutics Inc. Common Stock interactive price chart. Choose custom timeframes to analyze LABT price movements and trends.
LABT Company Profile
Discover essential business fundamentals and corporate details for Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
23 Apr 2026
Employees
5.00
Website
http://www.lakewoodamedex.comCEO
Kelvin Cooper
Description
This biopharmaceutical company is dedicated to developing innovative antimicrobial therapies. Its array of anti-infective products is designed to tackle specific viral conditions, including avian influenza, Epstein-Barr Virus (EBV), and hepatitis B and C. Established by Roderic Dale on July 11, 2006, the firm maintains its principal office in Bradenton, Florida.
LABT Financial Timeline
Browse a chronological timeline of Lakewood-Amedex Biotherapeutics Inc. Common Stock corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 28 Aug 2026
EPS estimate is $0.65.
Stock split effective on 22 Jun 2026
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 22 May 2026
EPS came in at -$1.32 .
LABT Stock Performance
Access detailed LABT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
